Clinical Study on the Impact of Eradication of Oral Porphyromonas Gingivalis on the Prognosis of Early Esophageal Cancer After ESD Surgery

Inclusion Criteria:

* Histologically confirmed esophageal cancer;
* Newly diagnosed patients who meet the absolute and relative indications for ESD;
* ECOG: 0～1;
* Expected survival ≥12 weeks;
* Receive ESD treatment within 28 days and meet R0 standards;
* The main organ functions are normal, that is, the following standards are met:

  1. Routine blood examination:

     a.HB≥90g/L; b.ANC≥1.5×10\^9/L; c.PLT ≥80×10\^9/L;
  2. Biochemical examination:

     1. ALB≥30g/L; b.ALT and AST≤2.5ULN; if there is liver metastasis, ALT and AST≤5ULN; c.TBIL≤1.5ULN;
* Women of childbearing potential must agree to use contraceptive measures (such as intrauterine devices, birth control pills or condoms) during the study and within 6 months after the end of the study; have a negative serum or urine pregnancy test within 7 days before study enrollment , and must be non-lactating patients; males should agree that they must use contraceptive measures during the study period and within 6 months after the end of the study period;
* The subjects voluntarily joined this study, signed the informed consent form, had good compliance, and cooperated with the follow-up.

Exclusion Criteria:

* Does not meet the above selection criteria;
* Patients with distant visceral metastasis;
* Pathological confirmation after ESD does not meet Tis, T1a, R0 or the depth of the lesion exceeds pSM1, and the depth of submucosal invasion is \>200 μm;
* The lesions are ulcerated and poorly differentiated (poorly differentiated, undifferentiated);
* There is lymphovascular infiltration;
* Those who are allergic to tinidazole or have metabolic disorders;
* Patients who require warfarin anticoagulation and those who cannot quit drinking;
* Patients who cannot tolerate ultrasonic tooth cleaning;
* Pregnant or lactating women;
* Patients with other malignant tumors within 5 years (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);
* Those who have a history of psychotropic drug abuse and are unable to quit or patients with mental disorders;
* Patients who have participated in other drug clinical trials within four weeks;
* Patients who, according to the researcher's judgment, have concomitant diseases that seriously endanger patient safety or affect the patient's completion of the study;
* Patients with recurrent oral ulcers or other oral diseases that affect oral flora;
* Patients with chronic infectious diseases or autoimmune diseases who require long-term or repeated application of antibacterial drugs or glucocorticoids; those deemed not suitable for inclusion by the researcher.
* The researcher believes that the applicant is not suitable for inclusion.